Zacks Investment Research Lowers Hikma Pharmaceuticals (OTCMKTS:HKMPF) to Hold

Share on StockTwits

Zacks Investment Research cut shares of Hikma Pharmaceuticals (OTCMKTS:HKMPF) from a buy rating to a hold rating in a report issued on Tuesday morning, Zacks.com reports.

According to Zacks, “Hikma Pharmaceuticals PLC develops, manufactures and markets pharmaceutical products. Its brand portfolio includes branded, injectables and generic. Branded segment offers dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system, oncology and respiratory. Injectables segment offers dosage for CNS, controlled substances, anti-infective, cardiovascular and oncology in form of liquid, semi-liquid and powdered form. Generics segment offers dosage for therapeutic including analgesic, anti-infective, anti-inflammatory, cardiovascular, CNS, respiratory and hormonal. Hikma Pharmaceuticals PLC is based in London, the United Kingdom. “

A number of other analysts have also recently weighed in on the company. ValuEngine upgraded Hikma Pharmaceuticals from a strong sell rating to a sell rating in a research note on Thursday, October 10th. Goldman Sachs Group initiated coverage on Hikma Pharmaceuticals in a research report on Tuesday, September 3rd. They set a buy rating on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. Hikma Pharmaceuticals has an average rating of Hold and an average price target of $25.00.

Shares of HKMPF traded up $0.20 during midday trading on Tuesday, hitting $26.00. 300 shares of the stock were exchanged, compared to its average volume of 56. Hikma Pharmaceuticals has a 52-week low of $19.80 and a 52-week high of $26.65. The firm has a market cap of $6.26 billion, a P/E ratio of 18.84 and a beta of 0.14. The stock has a fifty day simple moving average of $25.72 and a 200 day simple moving average of $23.83.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including oncology and anti-viral products to hospitals.

Featured Article: Blue-Chip Stocks

Get a free copy of the Zacks research report on Hikma Pharmaceuticals (HKMPF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks: Brokerages Expect Lamb Weston Holdings Inc  Will Post Earnings of $0.85 Per Share
Zacks: Brokerages Expect Lamb Weston Holdings Inc Will Post Earnings of $0.85 Per Share
SparksPay 24-Hour Trading Volume Tops $4.00
SparksPay 24-Hour Trading Volume Tops $4.00
Blocktrade Token  Reaches One Day Trading Volume of $944.00
Blocktrade Token Reaches One Day Trading Volume of $944.00
TrueChain Tops One Day Trading Volume of $9.35 Million
TrueChain Tops One Day Trading Volume of $9.35 Million
$0.53 Earnings Per Share Expected for Bank Of Princeton  This Quarter
$0.53 Earnings Per Share Expected for Bank Of Princeton This Quarter
Brokerages Set SAF-HOLLAND S.A.  PT at €8.86
Brokerages Set SAF-HOLLAND S.A. PT at €8.86


© 2006-2019 Ticker Report